Application of stimuli-responsive nanomedicines for the treatment of ischemic stroke
Ischemic stroke (IS) refers to local brain tissue necrosis which is caused by impaired blood supply to the carotid artery or vertebrobasilar artery system. As the second leading cause of death in the world, IS has a high incidence and brings a heavy economic burden to all countries and regions becau...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-02-01
|
| Series: | Frontiers in Bioengineering and Biotechnology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fbioe.2023.1329959/full |
| _version_ | 1797334817667284992 |
|---|---|
| author | Yongyi Zhan Yue Dai Zhejing Ding Mingtian Lu Zehua He Zhengwei Chen Yongkang Liu Zhongliang Li Guangsen Cheng Shaojun Peng Yu Liu |
| author_facet | Yongyi Zhan Yue Dai Zhejing Ding Mingtian Lu Zehua He Zhengwei Chen Yongkang Liu Zhongliang Li Guangsen Cheng Shaojun Peng Yu Liu |
| author_sort | Yongyi Zhan |
| collection | DOAJ |
| description | Ischemic stroke (IS) refers to local brain tissue necrosis which is caused by impaired blood supply to the carotid artery or vertebrobasilar artery system. As the second leading cause of death in the world, IS has a high incidence and brings a heavy economic burden to all countries and regions because of its high disability rate. In order to effectively treat IS, a large number of drugs have been designed and developed. However, most drugs with good therapeutic effects confirmed in preclinical experiments have not been successfully applied to clinical treatment due to the low accumulation efficiency of drugs in IS areas after systematic administration. As an emerging strategy for the treatment of IS, stimuli-responsive nanomedicines have made great progress by precisely delivering drugs to the local site of IS. By response to the specific signals, stimuli-responsive nanomedicines change their particle size, shape, surface charge or structural integrity, which enables the enhanced drug delivery and controlled drug release within the IS tissue. This breakthrough approach not only enhances therapeutic efficiency but also mitigates the side effects commonly associated with thrombolytic and neuroprotective drugs. This review aims to comprehensively summarize the recent progress of stimuli-responsive nanomedicines for the treatment of IS. Furthermore, prospect is provided to look forward for the better development of this field. |
| first_indexed | 2024-03-08T08:26:43Z |
| format | Article |
| id | doaj.art-b21c3e9013474a258bdf9e004c690b32 |
| institution | Directory Open Access Journal |
| issn | 2296-4185 |
| language | English |
| last_indexed | 2024-03-08T08:26:43Z |
| publishDate | 2024-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Bioengineering and Biotechnology |
| spelling | doaj.art-b21c3e9013474a258bdf9e004c690b322024-02-02T04:36:47ZengFrontiers Media S.A.Frontiers in Bioengineering and Biotechnology2296-41852024-02-011110.3389/fbioe.2023.13299591329959Application of stimuli-responsive nanomedicines for the treatment of ischemic strokeYongyi Zhan0Yue Dai1Zhejing Ding2Mingtian Lu3Zehua He4Zhengwei Chen5Yongkang Liu6Zhongliang Li7Guangsen Cheng8Shaojun Peng9Yu Liu10Zhuhai Interventional Medical Center, Cerebrovascular Diseases Department, Zhuhai Clinical Medical College of Jinan University (Zhuhai People’s Hospital), Zhuhai, ChinaZhuhai Interventional Medical Center, Cerebrovascular Diseases Department, Zhuhai Clinical Medical College of Jinan University (Zhuhai People’s Hospital), Zhuhai, ChinaZhuhai Interventional Medical Center, Cerebrovascular Diseases Department, Zhuhai Clinical Medical College of Jinan University (Zhuhai People’s Hospital), Zhuhai, ChinaZhuhai Interventional Medical Center, Cerebrovascular Diseases Department, Zhuhai Clinical Medical College of Jinan University (Zhuhai People’s Hospital), Zhuhai, ChinaZhuhai Interventional Medical Center, Cerebrovascular Diseases Department, Zhuhai Clinical Medical College of Jinan University (Zhuhai People’s Hospital), Zhuhai, ChinaZhuhai Interventional Medical Center, Cerebrovascular Diseases Department, Zhuhai Clinical Medical College of Jinan University (Zhuhai People’s Hospital), Zhuhai, ChinaZhuhai Interventional Medical Center, Cerebrovascular Diseases Department, Zhuhai Clinical Medical College of Jinan University (Zhuhai People’s Hospital), Zhuhai, ChinaZhuhai Interventional Medical Center, Cerebrovascular Diseases Department, Zhuhai Clinical Medical College of Jinan University (Zhuhai People’s Hospital), Zhuhai, ChinaZhuhai Interventional Medical Center, Cerebrovascular Diseases Department, Zhuhai Clinical Medical College of Jinan University (Zhuhai People’s Hospital), Zhuhai, ChinaZhuhai Institute of Translational Medicine, Zhuhai Clinical Medical College of Jinan University (Zhuhai People’s Hospital), Zhuhai, ChinaZhuhai Interventional Medical Center, Cerebrovascular Diseases Department, Zhuhai Clinical Medical College of Jinan University (Zhuhai People’s Hospital), Zhuhai, ChinaIschemic stroke (IS) refers to local brain tissue necrosis which is caused by impaired blood supply to the carotid artery or vertebrobasilar artery system. As the second leading cause of death in the world, IS has a high incidence and brings a heavy economic burden to all countries and regions because of its high disability rate. In order to effectively treat IS, a large number of drugs have been designed and developed. However, most drugs with good therapeutic effects confirmed in preclinical experiments have not been successfully applied to clinical treatment due to the low accumulation efficiency of drugs in IS areas after systematic administration. As an emerging strategy for the treatment of IS, stimuli-responsive nanomedicines have made great progress by precisely delivering drugs to the local site of IS. By response to the specific signals, stimuli-responsive nanomedicines change their particle size, shape, surface charge or structural integrity, which enables the enhanced drug delivery and controlled drug release within the IS tissue. This breakthrough approach not only enhances therapeutic efficiency but also mitigates the side effects commonly associated with thrombolytic and neuroprotective drugs. This review aims to comprehensively summarize the recent progress of stimuli-responsive nanomedicines for the treatment of IS. Furthermore, prospect is provided to look forward for the better development of this field.https://www.frontiersin.org/articles/10.3389/fbioe.2023.1329959/fullischemic strokestimuli-responsivenanomedicinemicro-environmentdrug delivery |
| spellingShingle | Yongyi Zhan Yue Dai Zhejing Ding Mingtian Lu Zehua He Zhengwei Chen Yongkang Liu Zhongliang Li Guangsen Cheng Shaojun Peng Yu Liu Application of stimuli-responsive nanomedicines for the treatment of ischemic stroke Frontiers in Bioengineering and Biotechnology ischemic stroke stimuli-responsive nanomedicine micro-environment drug delivery |
| title | Application of stimuli-responsive nanomedicines for the treatment of ischemic stroke |
| title_full | Application of stimuli-responsive nanomedicines for the treatment of ischemic stroke |
| title_fullStr | Application of stimuli-responsive nanomedicines for the treatment of ischemic stroke |
| title_full_unstemmed | Application of stimuli-responsive nanomedicines for the treatment of ischemic stroke |
| title_short | Application of stimuli-responsive nanomedicines for the treatment of ischemic stroke |
| title_sort | application of stimuli responsive nanomedicines for the treatment of ischemic stroke |
| topic | ischemic stroke stimuli-responsive nanomedicine micro-environment drug delivery |
| url | https://www.frontiersin.org/articles/10.3389/fbioe.2023.1329959/full |
| work_keys_str_mv | AT yongyizhan applicationofstimuliresponsivenanomedicinesforthetreatmentofischemicstroke AT yuedai applicationofstimuliresponsivenanomedicinesforthetreatmentofischemicstroke AT zhejingding applicationofstimuliresponsivenanomedicinesforthetreatmentofischemicstroke AT mingtianlu applicationofstimuliresponsivenanomedicinesforthetreatmentofischemicstroke AT zehuahe applicationofstimuliresponsivenanomedicinesforthetreatmentofischemicstroke AT zhengweichen applicationofstimuliresponsivenanomedicinesforthetreatmentofischemicstroke AT yongkangliu applicationofstimuliresponsivenanomedicinesforthetreatmentofischemicstroke AT zhongliangli applicationofstimuliresponsivenanomedicinesforthetreatmentofischemicstroke AT guangsencheng applicationofstimuliresponsivenanomedicinesforthetreatmentofischemicstroke AT shaojunpeng applicationofstimuliresponsivenanomedicinesforthetreatmentofischemicstroke AT yuliu applicationofstimuliresponsivenanomedicinesforthetreatmentofischemicstroke |